Mylan is an American pharmaceutical company headquartered in Canonsburg, Pennsylvania. It was founded in 1961 by Milan Puskar and Don Panoz, and initially focused on generic drugs. Over the years, Mylan has expanded its portfolio to include both generic and branded pharmaceuticals across various therapeutic areas.

Mylan's headquarters in Canonsburg spans an area of over 280,000 square feet and houses various departments including research and development, manufacturing, quality control, and administration. The company also has a global presence with operations in over 165 countries and sales in more than 165 countries. The company offers a wide range of products and services, including generic and branded prescription drugs, over-the-counter medications, and active pharmaceutical ingredients.

Mylan's primary focus areas include cardiovascular, central nervous system, diabetes, gastroenterology, respiratory, and women's health. Mylan has several noteworthy subsidiaries, joint ventures, and partnerships, which further enhance its global reach. Some of the notable collaborations include a joint venture with Biocon, Mylan-Biocon Biologics, to develop and market biosimilars across various regions.

Mylan also has strategic partnerships with companies like Pfizer and Fujifilm Kyowa Kirin Biologics. In terms of market position, Mylan is one of the largest generic pharmaceutical companies globally. It has consistently ranked among the top players in the industry in terms of global sales.

Mylan has established itself as a leading provider of affordable medications, making healthcare accessible to a wide population. Over the years, Mylan has achieved significant milestones, including the acquisition of certain businesses from Abbott Laboratories and the merger with Upjohn, a division of Pfizer. These strategic moves have expanded Mylan's product portfolio and global presence, positioning it for continued growth and success in the pharmaceutical industry.

As of the latest updates, Mylan is now known as Viatris following the completion of the merger with Upjohn in November 2020. Viatris is a global healthcare company committed to expanding access to medicines and improving patient outcomes. Through its diversified product portfolio and global presence, Viatris aims to address unmet medical needs and improve the well-being of patients worldwide